US$ 22.68
glp-1 drug names The Rise of Medications – Magnet The first weight loss drugs
Description
As patient demand accelerates and care models shift toward long-term, outcomes-driven weight management, having the right operational foundation is critical
28 , 29 Subgroup analyses from various cardiovascular outcomes trials have also shown that GLP-1 RAs may benefit kidney-related outcomes, including reductions in albuminuria, slower declines in estimated glomerular filtration rate, and a decreased risk of end-stage kidney disease in patients with and without diabetes

10.1038/s41433-021-01741-5 91

Weight regain is the most likely outcome

2008;198(4):416 e1-426
